These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 18688784)

  • 1. Design of anticancer prodrugs for reductive activation.
    Chen Y; Hu L
    Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of hypoxia-activated prodrugs in cancer therapy.
    Denny WA
    Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.
    Peacock AF; Sadler PJ
    Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat.
    Failes TW; Hambley TW
    J Inorg Biochem; 2007 Mar; 101(3):396-403. PubMed ID: 17197030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mechanisms of activation of indolequinone phosphoramidate prodrugs.
    Hernick M; Borch RF
    J Med Chem; 2003 Jan; 46(1):148-54. PubMed ID: 12502368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
    Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
    J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
    Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
    Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymeric anticancer drugs with pH-controlled activation.
    Ulbrich K; Subr V
    Adv Drug Deliv Rev; 2004 Apr; 56(7):1023-50. PubMed ID: 15066758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
    El-Dakdouki MH; Adamski N; Foster L; Hacker MP; Erhardt PW
    J Med Chem; 2011 Dec; 54(23):8224-7. PubMed ID: 22011244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
    Hasinoff BB; Begleiter A
    Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do prodrugs deliver?
    Smith DA
    Curr Opin Drug Discov Devel; 2007 Sep; 10(5):550-9. PubMed ID: 17786853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
    Henderson ND; Plumb JA; Robins DJ; Workman P
    Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclopropyl indolequinones: mechanistic probes for bioreductive anticancer drug action.
    Moody CJ; Norton CL; Slawin AM; Taylor S
    Anticancer Drug Des; 1998 Sep; 13(6):611-34. PubMed ID: 9755721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
    Hunter FW; Jaiswal JK; Hurley DG; Liyanage HD; McManaway SP; Gu Y; Richter S; Wang J; Tercel M; Print CG; Wilson WR; Pruijn FB
    Biochem Pharmacol; 2014 May; 89(2):224-35. PubMed ID: 24632291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
    Wilson WR; Tercel M; Anderson RF; Denny WA
    Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitro reduction as an electronic switch for bioreductive drug activation.
    Siim BG; Denny WA; Wilson WR
    Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
    Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
    Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of self-immolative linkers for tumour-activated prodrug therapy.
    Tranoy-Opalinski I; Fernandes A; Thomas M; Gesson JP; Papot S
    Anticancer Agents Med Chem; 2008 Aug; 8(6):618-37. PubMed ID: 18690826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.
    Nemirovski A; Vinograd I; Takrouri K; Mijovilovich A; Rompel A; Gibson D
    Chem Commun (Camb); 2010 Mar; 46(11):1842-4. PubMed ID: 20198227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.